Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
NCT06128733
Active Not Recruiting
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
01/10/2025
Locations: Accel Research Site - Birmingham Clinical Research Unit- Site Number : 8400080, Birmingham, Alabama +46 locations
Conditions: Healthy Volunteers, Meningococcal Immunisation
Register for Updates
IBRX-042 in Participants with HPV-Associated Tumors
NCT05976828
Recruiting
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are: * What is the maximum tolerated dose of IBRX-042? * How well does the study drug treat cancer? * What effects the study drug may have on the human body and cancer? Participants will receive IBRX-042 at one of... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/10/2025
Locations: Chan Soon-Shiong Institute for Medicine (CSSIFM), El Segundo, California +2 locations
Conditions: HPV-Related Carcinoma
Register for Updates
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
NCT04580771
Active Not Recruiting
This phase IIA trial studies the effect of a vaccine (PDS0101) when given together with chemotherapy and radiation therapy (chemoradiation) in treating patients with stage IB3-IVA cervical cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. PDS0101 is a type of vaccine... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Register for Updates
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
NCT04015700
Active Not Recruiting
This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Glioblastoma
Register for Updates
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
NCT02600949
Recruiting
This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Systems Biological Assessment of Statin Effect on Vaccine Responses
NCT06024096
Completed
This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand how this medication affects long-lasting immune responses to vaccines. The researchers will study the immune response to the influenza vaccine in the blood (where antibodies are). The team will also look at how statin therapy affects the bacteria that live in the gut by... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/06/2025
Locations: Hope Clinic, Atlanta, Georgia
Conditions: Vaccine Response
Register for Updates
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
NCT04639466
Active Not Recruiting
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. GEO-CM04S1 was created by placing small pieces of SARS-CoV-2 DNA (the chemica... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/02/2025
Locations: EmVenio Research, Claremont, California +2 locations
Conditions: COVID-19 Infection
Register for Updates
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124
Active Not Recruiting
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 3 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle. Stage 2 will begin after... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Alliance for Multispecialty Research, LLC, Coral Gables, Florida +16 locations
Conditions: Pneumococcal Disease
Register for Updates
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
NCT03153410
Completed
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
NCT05827926
Completed
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults. The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and \<50 years of age.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
12/21/2024
Locations: Chandler Clinical Trials, Chandler, Arizona +68 locations
Conditions: SARS-CoV-2, Influenza
Register for Updates
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
NCT04206813
Active Not Recruiting
The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to that observed of a 3-dose schedule of Gardasil 9 among women aged 16-26 years old. The investigators thought that having a 2-dose vaccination regimen for individuals 16 to 45 would provide a more robust dataset than those of 27 to 45 years old.
Gender:
FEMALE
Ages:
Between 16 years and 45 years
Trial Updated:
12/20/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: HPV Infection
Register for Updates
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
NCT05089630
Active Not Recruiting
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens adjuvanted, regardless of baseline CMV sero-status. This FTiH study will be conducted in healthy adults 18 to 50 years of age, in which the 4 dose levels of the vaccine will be administered in a step-wise dose escalation manner, based upon safety adjudication.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/20/2024
Locations: GSK Investigational Site, Anaheim, California +17 locations
Conditions: Cytomegalovirus Infections
Register for Updates